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vs. 62.2%, p= 0.24), but reported higher mean levels of absenteeism (12.64% vs. 5.00%, 
p= 0.0014), presenteeism (32.71% vs. 15.49%, p< 0.0001), overall work impairment 
(37.32% vs. 18.26%, p< 0.0001) and activity impairment (45.93 vs. 26.90, p< 0.0001) 
relative to controls. Mean health care utilization in the prior 6 months was greater 
among cases than controls for visits to traditional health care providers (8.39 vs. 
5.03, p< 0.0001), general practitioners (1.72 vs. 1.25, p= 0.0043), allergists (0.49 vs. 0.07, 
p< 0.0001), dermatologists (0.40 vs. 0.16, p= 0.0004), emergency rooms (0.50 vs. 0.33, 
p= 0.0608), and hospitalizations (0.36 vs. 0.23, p= 0.0985). ConClusions: Using CH 
as a proxy for CIU, a considerable economic burden on patients was evident in work 
productivity and use of health care compared to patients without CH with similar 
sociodemographic characteristics.
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objeCtives: To compare the number of 1st-line and 2nd-line intravitreal anti-
VEGF injections and associated costs in patients with neovascular age-related 
macular degeneration (AMD) treated with aflibercept (AFB) or ranibizumab 
(RBZ). Methods: A retrospective cohort study of US claims data of patients 
who: initiated 1st- or 2nd-line ITV anti-VEGF treatment with RBZ or AFB between 
1/18/2011 and 7/31/2013 (index date), had no evidence of bilateral disease, were 
aged ≥ 18 years on index date, had ≥ 12 months of continuous insurance enrollment 
before index date (baseline period), were diagnosed with AMD (ICD-9-CM 362.52) 
during baseline period or on index date, and had ≥ 12 months of follow-up enroll-
ment post index date without switching anti-VEGF agents. Outcomes (number of 
anti-VEGF injections and their associated costs) were assessed within 12-month 
follow-up period. Multivariable regressions compared outcomes between AFB and 
RBZ, adjusting for confounding patient characteristics. Results: A total of 115 
1st-line AFB, 431 2nd-line AFB, 481 1st-line RBZ, and 174 2nd-line RBZ patients met 
the inclusion criteria. Mean [SD] number of injections was similar for AFB and RBZ 
patients for 1st- (5.0 [2.7] and 5.0 [3.1], respectively) and 2nd-line (5.7 [2.5] and 5.8 
[3.1], respectively). Mean anti-VEGF therapy-related costs [SD] were comparable for 
AFB and RBZ patients for 1st- ($9,155 [$11,420] and $9,241 [$10,547], respectively) 
and 2nd-line ($10,485 [$11,734] and $10,935 [$13,411], respectively). Multivariable 
regression determined that, for both 1st- and 2nd-line patients, neither number 
nor costs of injections differed significantly between AFB and RBZ (treating RBZ 
as reference: Incidence Rate Ratio [IRR]= 0.99, 95% confidence interval [CI]= 0.87-
1.13, P= 0.871 [1st-line]; IRR= 0.97, 95%CI= 0.88-1.06, P= 0.476 [2nd-line]; Cost Ratio 
[CR]= 0.96, 95%CI= 0.82-1.11, P= 0.582 [1st-line]; CR= 0.89, 95%CI= 0.79-1.01, P= 0.064 
[2nd-line]). ConClusions: Injection frequency and costs over 12 months were 
similar for AFB and RBZ in this analysis of AMD patients initiating 1st- or 2nd-line 
anti-VEGF treatment in a real-world setting.
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objeCtives: The objective of this study was to describe health care costs associ-
ated with the management of psoriasis in patients newly initiated on a biologic 
or methotrexate (MTX). Methods: Continuously enrolled adult patients with ≥ 2 
inpatient or outpatient psoriasis diagnoses were selected from the MarketScan 
Commercial Claims database (2005-2009). The first biologic or MTX prescription 
date was defined as the index date. “MTX initiators” had not used biologics, non-
biologic conventional systemic therapies, or phototherapy 6 months before the 
index date. “Biologic initiators” were required to be biologic-naïve only before the 
index date. Health care costs were estimated from a US payer perspective (2011 
US dollars) over the 12-month period following the index date, based on payments 
for all medical services and psoriasis related diagnosis as a subset. Physician 
office visits, monitoring, inpatient hospitalizations, and emergency department 
visits were also captured. Results: A total of 2,642 MTX initiators and 6,702 bio-
logic initiators met the eligibility criteria. MTX initiators had a mean annual total 
health care cost of $12,548, of which 30.7% was psoriasis-related. Pharmacy costs 
accounted for $3,182 of the psoriasis-related costs, office care and monitoring 
costs accounted for $501, and urgent care costs accounted for $166. Biologic initia-
tors had an average annual total health care cost of $28,752, of which 72.0% was 
psoriasis-related. Pharmacy costs accounted for $19,997 of the psoriasis-related 
total costs, office care and monitoring cost for $538, and urgent care costs for 
$166. ConClusions: Psoriasis patients initiating on MTX or a biologic incurred 
substantial health care costs. Pharmacy costs account for the majority of the 
psoriasis-related costs.
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study worldwide investigating the burden of disease. Myopic CNV-related costs of 
care are substantial and increasing with the severity of vision loss.
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objeCtives: Estimate health care utilization and costs of co-morbidities in patients 
with psoriasis. Methods: A retrospective cohort analysis was conducted using 
the Truven MarketScan data®. Inclusion criteria were adult patients with at least 
2 diagnosis of psoriasis (ICD-9-CM: 696.1) on different dates between January 1st, 
2010 and December 31st, 2011, with at least one psoriasis diagnosis in year 2010 
and with continuous enrollment of medical and pharmacy benefits in year 2010 
and 2011. Patients were divided into two groups with and without comorbidity of 
interest in year 2010. Multiple regressions were conducted to compare all cause 
health care utilization (Poisson regression) and costs (gamma regression or two 
part models; 95% confidence intervals (CI) were calculated using bootstrapping 
method) in year 2011 between patients with and without comorbidity of interest, 
controlling for age, gender, and region and psoriasis severity in year 2010. Results: 
A total of 56,406 patients (mean age 51.71 years) were included in the analyses. 
The top five prevalent co-morbidities were hypertension (34.49%), hyperlipidemia 
(33.79%), cardiovascular disease (17.44%), diabetes (14.36%) and psoriatic arthritis 
(9.94 %). The all cause incidence rate ratio (95% CI) of emergency room visits, hos-
pitalization, outpatient visits for patients with at least one co-morbidity was 1.84 
(1.75-1.94); 2.03 (1.87-2.19); 1.49 (1.47-1.51) respectively compared to patients with 
no co-morbidities (all, p< 0.0001). The adjusted all cause health care costs difference 
was $6640 ($6255-$7024) for patients with co-morbidities as compared patients 
with no co-morbidities. The mean (95% CI) all cause adjusted cost difference for 
psoriatic patients with co-morbidities as compared to psoriatic patients without co-
morbidities was $4,522 ($4034-$5011), $1,635 ($1,188-$2,082), $8,275.1 ($7,461-$9,089), 
$6,911 ($6,271-$7,552) and $9,914 ($9,216-$10,613) for hypertension, hyperlipidemia, 
cardiovascular disease, diabetes and psoriatic arthritis respectively. ConClusions: 
Comorbidities continue to have a significant economic burden in patients with 
psoriasis in the United States.
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objeCtives: Estimate direct and indirect costs of depression and anxiety in 
patients with psoriasis (PsO). Methods: Retrospective cohort analysis was con-
ducted using Truven MarketScan data®. Adult patients with at least 2 diagnosis of 
PsO (ICD-9-CM: 696.1) between year 2010 and 2011 (at least one PsO diagnosis in 
year 2010) having continuous enrollment of medical and pharmacy benefits were 
included. Patients with Health and Productivity Management data for 2011 were 
included for the indirect cost analysis, including costs associated with absence 
of leave (ABS), short term disability (STD), and long term disability (LTD). Indirect 
costs were calculated using average 2011 hourly wage data for all US private indus-
tries (number of ABS/STD/LTD days * 8 hours * an average hourly wage). Multiple 
regressions were conducted to compare year 2011 direct costs and indirect costs 
(gamma regression or two part models) between patients with and without depres-
sion or anxiety respectively, controlling for age, gender, and region and PsO sever-
ity in year 2010. Results: Among a total of 56,406 PsO patients (mean age 52 
years), 7.9% patients with depression and 5.7% with anxiety in year 2010 were 
included in the direct cost analyses. A total of 1,434 patients for ABS, 5,878 for 
STD and 5,692 for LTD were included in the indirect cost analyses. The adjusted 
health care costs were significantly higher for patients with depression ($20,794 
vs. $14,028) or anxiety ($18,501 vs. $14,320) than those without (p< 0.001 for all). 
The major differences between indirect costs were STD costs whereby the adjusted 
mean difference between patients with depression vs. without depression were 
$997 (95% confidence interval (CI) $432-1561), between patients with anxiety vs. 
without was $268 (95% CI $-158-790). ConClusions: Significant proportion of PsO 
patients had depression and anxiety, and patients with depression and anxiety 
have substantial higher direct and indirect costs than those without.
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objeCtives: To assess the economic burden of patients with chronic idiopathic 
urticaria (CIU) in terms of labor force participation, work and activity impairment, 
and health care utilization, using patients currently treated for chronic hives 
(CH) as a proxy. Methods: Data were obtained from the US National Health and 
Wellness Survey (NHWS) in 2010-2012, representative of US adult population in 
terms of age, sex, and ethnicity. Measures included labor force participation, the 
Work Productivity and Activity Impairment questionnaire, and self-reported health 
care use in the prior 6 months. Respondents indicating current use of a prescrip-
tion for CH (cases) were matched 1:4 to those who never experienced CH (controls), 
using survey year, sex, race, age (±2 years), and Charlson comorbidity index (CCI) 
category (0, 1-2, 3-4, or 5+), and compared using t-test and chi-square. Results: 
Cases (n= 253) and controls (n= 1,012) did not significantly differ in terms of age, 
body mass index, marital status, educational attainment, or mean CCI (all p> 0.05). 
Currently-treated CH patients participated in the labor force at a similar rate (58.1% 
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objeCtives: evaluate the cost-effectiveness of the use of toric intraocular lenses 
(IOLs) in surgery of patients with cataract and preexisting corneal astigmatism (> 
0.75 D), versus the use of traditional monofocal intraocular lenses (IOLs) from the 
perspective of third party payer, as a way to define which technology could consid-
ered in the health care reimbursement. Methods: in a decision tree type model 
was simulated the cataracts surgery intervention in a time horizon of five years. The 
outcome measure was the cumulative visual acuity of 20/32, which was expressed 
in normal vision time without additional support. The drug costs were taken from 
SISMED (2013), the costs from multi-core procedures of the health ministry (SISPRO), 
the cost of glasses and contact lenses from commercial channel, and the cost of 
IOLs were taken as the selling price of Alcon Laboratories. Finally a Montecarlo type 
sensitivity analysis was performed. Results: as primary outcome, time normal 
distance vision without additional support was higher with toric IOLs, which it were 
more effective at 3,64 years versus 2,97 years achieved with traditional monofocal 
IOLs. Intervention with toric IOLs showed in the time horizon of five years be more 
expensive with (USD) $1.093,55 versus costs of traditional monofocal IOLs (USD) 
$732,71. In this regard cataract surgery is more effective and more costly with toric 
IOLs than with traditional monofocal IOLs with an incremental cost-effectiveness 
ratio of (USD) $534,83 per each year of normal vision without additional support. It 
was observed that the ICER improves if there is a greater visual impairment due to 
astigmatism before surgery, as well, to diopters < 1.50, > 1.50 < 2.00 and > 2.00 the ICER 
was (USD) $ 712.40, (USD) $ 416.75 and (USD) $ 382.16 respectively. ConClusions: 
toric IOLs proved to be cost-effective for the treatment of patients with cataract 
and preexisting astigmatism.
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cOSt-effectiVeneSS Of ranibizUMab VerSUS laSer in tHe treatMent Of 
ViSUal iMPairMent dUe tO diabetic MacUlar OedeMa (dMe) frOM tHe 
cOlOMbian HealtH care SySteM PerSPectiVe
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Novartis, Bogotá, Colombia
objeCtives: To evaluate the cost effectiveness, from the Colombian health care 
system perspective, of ranibizumab monotherapy or ranibizumab combined with 
laser against laser monotherapy for the treatment of diabetic macular edema 
(DME). Methods: A Markov model was designed to simulate the clinical and eco-
nomic benefits associated with ranibizumab as either monotherapy or combined 
with laser versus laser monotherapy in the treatment of visual impairment due 
to DME. The effectiveness outcomes measured were the life years without visual 
impairment based on RESTORE 3-year follow-up data. Over 15-year time horizon 
annual cycles were performed. The costs involved in the model were taken from 
the official medication cost database in Colombia (SISMED) and 6 Colombian health 
care providers (IPS) The analysis, according to the RESTORE study, considered that 
22 % of patients received treatment on both eyes. For ranibizumab and laser group, 
the first three years transition probabilities where taken from the same study and 
for the laser group the second and third year data was taken from the Diabetic 
Retinopathy Clinical Research Network (DRCR.net ). Results: Ranibizumab mono-
therapy showed a gain of 0.30 years with no visual impairment at an incremental 
cost of COP 8, 272, 248 (USD 4.273,01) relative to laser monotherapy, resulting in 
an incremental cost- effectiveness ratio (ICER) of COP 28,041,494 (USD $14.484,77). 
Likewise ranibizumab monotherapy was superior to combination therapy with an 
ICER of COP 34,224,675 (USD $17.678, 67) in a time horizon of 15 years. Probabilistic 
sensitivity analysis placed ranibizumab monotherapy as a more cost-effective alter-
native versus laser monotherapy in 95% of the cases. ConClusions: The results 
pointed out that ranibizumab both as a monotherapy as well as combined with 
laser therapy are cost-effective alternatives from the Colombian health care system 
perspective.
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Paediatric OPHtHalMOlOgical PrOcedUreS
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objeCtives: Hospitals are a favorable environment for early health technology 
assessment (HTA) and cross-over designs are ideally suited for this. For example, 
young children who cannot tolerate eye examinations may require examination 
under anesthesia (EUA) in an operating room. Examination under chloral hydrate 
sedation (EUS) in an outpatient clinic may be a convenient and cost-effective 
alternative. The objective was to determine the incremental cost of EUS com-
pared to EUA per additional successful procedure gained from a societal perspec-
tive. Methods: A cost-effectiveness analysis was conducted using a retrospective 
cross-over cohort of 80 children that had both EUS and EUA. Direct costs included 
health professional services, supplies and equipment and indirect costs included 
parent productivity losses. Outcomes included the number of successful proce-
dures and adverse events (AEs). One-way and probabilistic sensitivity analyses 
were conducted. Results: The mean cost per patient was $406 (95% CI $401, 
$411) for EUS and $1,135 (95% CI $1,125, $1,145) for EUA. The mean number of 
successful procedures per patient was 1.39 (95% CI 1.34, 1.42) for EUS and 2.06 
(95% CI 2.02, 2.11) for EUA. EUS was $729 less costly on average than EUS but 
resulted in 0.68 fewer successful procedures per child. Three AEs occurred in 2 
EUS patients compared to 1 in the EUA group. The result was robust to varying 
objeCtives: Retinitis Pigmentosa (RP) is a hereditary genetic disease causing bilateral 
retinal degeneration. RP is a leading cause of blindness resulting in incurable visual 
impairment and drastic reduction in the Quality of life of the patients. Although the 
condition is at present incurable, advances in the field of retinal implants demonstrate 
the progress now being made in combating the condition and restoring a measure of 
sight to those afflicted. The objective of this study was to assess the cost-effectiveness 
of first ever-commercial implant intended to restore some vision in the Retinitis 
Pigmentosa (RP) patients. Methods: A multi -state transition Markov model was 
developed to determine the cost-effectiveness of retinal transplant versus usual care 
in RP from the perspective of health care payer. A hypothetical cohort of 1000 RP 
patients aged 46 years followed up over a (lifetime) 25-year time horizon. Health 
outcomes were expressed as quality adjusted life years (QALYs) and direct health care 
costs expressed in 2012 € . Results are reported as incremental cost per ratios (ICERs) 
with outcomes and costs discounted at an annual rate of 3.5%. Results: The ICER for 
the retinal implant was € 14,603 /QALY. Taking into account the uncertainty in model 
inputs the ICER was € 14,482/QALY in the probabilistic analysis. In the scenarios of 
an assumption of no reduction on cost across model visual acuity states or a model 
time horizon as short as 10 years the ICER increased to € 31,890/QALY and € 49,769/
QALY respectively. ConClusions: This economic evaluation shows that the retinal 
implant is a cost-effective intervention compared to usual care of the RP patients. 
The ICER for retinal implant falls below the published societal willingness to pay 
of EuroZone countries. Retinal implants could eventually change the lives of up to 
200,000 people worldwide who suffer from blindness due to Retinitis Pigmentosa.
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objeCtives: Prostaglandin analogues (PGAs) lower ophthalmic intraocular pres-
sure (IOP) and are widely used as first-line therapies in the management of ocular 
hypertension (OH) or primary open-angle glaucoma (POAG). They are more costly 
than alternative agents and this may impose a financial burden on patients as 
treatment is life-long. This study sought to evaluate the cost-effectiveness of four 
PGAs, bimatoprost, latanoprost, tafluprost and travoprost, as first-line monotherapy 
in patients with OH or POAG to inform formulary decision on the optimal agents to 
stock in a local hospital. Methods: A decision-analytic model was developed to 
simulate a cohort of patients with OH or POAG receiving PGA or timolol treatment 
over a one-month time horizon. The effectiveness data used were the proportion of 
patients achieving a clinical target of at least a 30% reduction in IOP from baseline 
and the incidence of hyperemia, a common side effect of PGAs. Treatment success 
and hyperemia rates were extracted from published literature and synthesised 
using a network meta-analysis. Cost of medications and doctor visits were included, 
in accordance with the adopted patient’s perspective, and this information was 
obtained from the hospital. The results were expressed as incremental cost per 
additional patient achieving clinical success. Deterministic sensitivity analyses 
were conducted to assess the robustness of the results. Results: Latanoprost and 
bimatoprost had a positive incremental cost-effectiveness ratio (ICER) of SGD 168 
and SGD 200, respectively, relative to timolol. Both travoprost and tafluprost were 
dominated by latanoprost. The results were most sensitive to the proportion of 
patients achieving at least a 30% IOP reduction from baseline and the cost of medica-
tions. ConClusions: This analysis suggests that latanoprost and bimatoprost are 
preferred among the four PGAs in terms of cost-effectiveness. Cost-effectiveness 
should be considered alongside other factors including comparative clinical efficacy 
and safety to make an informed formulary decision.
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objeCtives: Optometric services are not publicly funded in Prince Edward Island 
(PEI). This analysis aimed to assess the cost-effectiveness of funding optometrists 
for diabetic eye care versus funding general practitioners (GPs) for such services in 
PEI using PEI government’s health care payer perspective. Methods: A Markov 
cohort model of diabetic retinopathy (DR) was developed using PEI disease data 
(diabetic incidence, DR incidence and mortality), PEI cost data, and the data from 
the literature (utilities, DR progression). In the base-case, biannual screening of 
DR was assumed. A hypothetical cohort of diabetic patients of 35 years and older 
in PEI (8,392) was simulated to estimate expected lifetime health outcomes (non-
proliferative cases, proliferative cases, mortality, quality-adjusted life years (QALYs)) 
and cost (screening cost, treatment of proliferation retinopathy). Primary outcomes 
were expected QALYs, cost and incremental cost per QALY gained. Sensitivity analy-
ses were conducted to examine the robustness of the results. QALYs and costs were 
discounted at 5%. Results: In the base-case, biannual screening and treatment of 
DR by optometrists was determined as a cost-saving strategy compared to GP deliv-
ered service. The model was most sensitive to the health utility of diabetic patients, 
and screening rates provided by GPs. Varying the discount rate from 0 to 5% had 
the least impact on the cost-effectiveness of screening results. In other screening 
scenarios (annual and biennial), services provided by optometrists appeared to be 
very cost-effective, or even cost-savings compared to services delivered by GPs. The 
estimated potential financial savings to PEI government could be between Canadian 
dollar (C$) 45,000 to C$390,000 during 1 year to 10-year horizon if optometric services 
were publicly funded. ConClusions: Publicly funded screening and treatment 
of DR by optometrists in PEI is potentially a cost-saving strategy compared to the 
usual care provided by GPs.
